Skip to search formSkip to main contentSkip to account menu

paricalcitol

Known as: 19-Nor-1alpha,25-dihydroxyvitamin D2, paricalcitol [Chemical/Ingredient], (7e,22e)-19-Nor-9,10-Secoergosta-5,7,22-Triene-1Alpha,3Beta,25-Triol 
A synthetic noncalcemic, nonphosphatemic vitamin D analogue. Paricalcitol binds to the vitamin D receptor and has been shown to reduce parathyroid… 
National Institutes of Health

Related topics

Related topics

11 relations
CholecalciferolDrug AllergyDrug toxicityHypercalcemia

Broader (1)

Ergocalciferols

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Paricalcitol inhibits the Wnt/beta-catenin signaling pathway and ameliorates experimentally induced arthritis
Background/aim: The Wnt/ß-catenin pathway has important biological activities, including the differentiation of cells and joint… 
2017
2017
Effects of paricalcitol on biomarkers of inflammation and fibrosis in kidney transplant recipients: results of a randomized controlled trial.
AIMS Paricalcitol, a selective vitamin D activator, decreases proteinuria and may reduce graft failure risk in kidney transplant… 
2016
2016
[Treatment of secondary hyperparathyroidism in hemodialysed patients--paricalcitol with or without cinacalcet].
Secondary hyperparathyroidism (sHPT) is a common complication being a consequence of metabolic disorders associated with chronic… 
2015
2015
Changes in Plasma Levels of Asymmetric Dimethylarginine in Chronic Kidney Disease Patients Treated for 8 Weeks with the Vitamin D Receptor Agonist Paricalcitol
Objective: We investigated the effect of the vitamin D receptor agonist (VDRA), paricalcitol on biomarkers of endothelial… 
2014
2014
Efficacy and initial dose determination of paricalcitol for treatment of secondary hyperparathyroidism in Chinese subjects.
AIM Prevalence of secondary hyperparathyroidism (SHPT), a renal disease complication, is increasing in China. Available therapies… 
2011
2011
Efectividad del tratamiento con paricalcitol por vía oral en pacientes con enfermedad renal crónica en etapas anteriores a la diálisis
El hiperparatiroidismo secundario es una complicacion habitual en pacientes con insuficiencia renal cronica. El tratamiento con… 
2010
2010
Pharmacists find satisfaction in dialysis clinics.
For pharmacists who work in dialysis clinics, satisfaction comes from meeting daily technical challenges and finding ways to… 
2009
2009
The Effect of Paricalcitol on Osteoprotegerin Production by Human Peripheral Blood Mononuclear Cells
It has been known for years that the ratio of receptor activator of nuclear factor-κB ligand (RANKL) relative to its decoy… 
2007
2007
Kostenbewertung von Arzneimitteln - Tagestherapiekosten und Defined Daily Doses am Beispiel von Paricalcitol
! The WHO originally introduced defined daily doses (DDD) for drug quantity comparisons. The term DDD describes the quantity of a… 
Review
2006
Review
2006
Cardiovascular disease in chronic kidney failure: the role of VDR activators.
Vitamin D3 is modified by vitamin D3 25-hydroxylase in the liver, and by 25-hydroxyvitamin D3 1alpha-hydroxylase (CYP27B1) in the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)